<?xml version='1.0' encoding='utf-8'?>
<document id="23431112"><sentence text="Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study."><entity charOffset="10-22" id="DDI-PubMed.23431112.s1.e0" text="ketoconazole" /><entity charOffset="54-72" id="DDI-PubMed.23431112.s1.e1" text="11β-hydroxysteroid" /><pair ddi="false" e1="DDI-PubMed.23431112.s1.e0" e2="DDI-PubMed.23431112.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23431112.s1.e0" e2="DDI-PubMed.23431112.s1.e1" /></sentence><sentence text="ABT-384 [1-piperazineacetamide, N-[5-(aminocarbonyl) tricyclo[3"><entity charOffset="0-30" id="DDI-PubMed.23431112.s2.e0" text="ABT-384 [1-piperazineacetamide" /><entity charOffset="32-63" id="DDI-PubMed.23431112.s2.e1" text="N-[5-(aminocarbonyl) tricyclo[3" /><pair ddi="false" e1="DDI-PubMed.23431112.s2.e0" e2="DDI-PubMed.23431112.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23431112.s2.e0" e2="DDI-PubMed.23431112.s2.e1" /></sentence><sentence text="3" /><sentence text="1" /><sentence text="13,7]dec-2-yl]-α,α-dimethyl-4-[5-(trifluoromethyl)-2-pyridinyl]-,stereoisomer] is a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1)"><entity charOffset="118-136" id="DDI-PubMed.23431112.s5.e0" text="11β-hydroxysteroid" /></sentence><sentence text=" ABT-384 has been shown to be safe and well tolerated in humans at doses up to 100 mg daily, and to fully inhibit both peripheral and brain HSD-1 at a dose of 2 mg daily" /><sentence text=" The effect of ketoconazole on the pharmacokinetics of ABT-384 and its two active metabolites, A-1331480 and A-847082, was investigated in healthy volunteers"><entity charOffset="15-27" id="DDI-PubMed.23431112.s7.e0" text="ketoconazole" /></sentence><sentence text=" When 10 mg of ABT-384 was coadministered with ketoconazole, ABT-384 exposures increased 18-fold for area under the plasma concentration-time curve from time 0 to infinity and 3"><entity charOffset="47-59" id="DDI-PubMed.23431112.s8.e0" text="ketoconazole" /></sentence><sentence text="5-fold for Cmax" /><sentence text=" The results suggest that ABT-384 is a sensitive substrate of CYP3A" /><sentence text=" After ketoconazole coadministration, exposures of A-1331480 and A-847082 were also greatly increased"><entity charOffset="7-19" id="DDI-PubMed.23431112.s11.e0" text="ketoconazole" /></sentence><sentence text=" A population pharmacokinetic model was constructed for ABT-384 and its metabolites using NonMEM" /><sentence text=" A two-compartment model with three transit absorption compartments best described ABT-384 data" /><sentence text=" The model predicted a 69" /><sentence text="3% decrease in ABT-384 clearance and 91" /><sentence text="1% increase in the volume of distribution of ABT-384 in the presence of ketoconazole"><entity charOffset="72-84" id="DDI-PubMed.23431112.s16.e0" text="ketoconazole" /></sentence><sentence text=" A-1331480 was shown to be formation rate-limited and A-847082 was elimination rate-limited" /><sentence text=" Both metabolites were characterized by a one-compartment model with first-order rate constants of formation and elimination" /><sentence text=" Overall the model adequately captured the concentration-time profiles of ABT-384, A-1331480, and A-847082 in both ABT-384-alone and ketoconazole-coadministration conditions"><entity charOffset="115-128" id="DDI-PubMed.23431112.s19.e0" text="ABT-384-alone" /><entity charOffset="133-145" id="DDI-PubMed.23431112.s19.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23431112.s19.e0" e2="DDI-PubMed.23431112.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23431112.s19.e0" e2="DDI-PubMed.23431112.s19.e1" /></sentence><sentence text=" Although ABT-384 exposures were greatly increased in the presence of ketoconazole, coadministration of ABT-384 with ketoconazole or other strong/moderate CYP3A inhibitors is not expected to contribute to any major clinical safety issues considering the favorable safety profile of ABT-384"><entity charOffset="70-82" id="DDI-PubMed.23431112.s20.e0" text="ketoconazole" /><entity charOffset="117-129" id="DDI-PubMed.23431112.s20.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23431112.s20.e0" e2="DDI-PubMed.23431112.s20.e0" /><pair ddi="false" e1="DDI-PubMed.23431112.s20.e0" e2="DDI-PubMed.23431112.s20.e1" /></sentence><sentence text="" /></document>